Teprotumumab shows convincing phase 3 outcomes for thyroid eye disease

• Posted on: Feb 13 2020
• By: Saratoga Opthalmology
• Leave a response

This a randomized, double-masked, placebo-controlled, phase 3 multicenter trial evaluating the insulin-like growth factor I receptor (IGF-IR) inhibitor teprotumumab for treating thyroid eye disease.
Source: AAO

Posted in: Uncategorized